Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 10/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11118610 | 0.83 | KMT2A (0.72) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL8206174 | 0.81 | KMT2A (1.00) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL1111137 | 0.81 | KMT2A (0.68) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL1421430 | 0.80 | KMT2A (1.00) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL11118190 | 0.80 | KMT2A (0.68) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL181796 | 0.80 | KMT2A (0.69) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL3041005 | 0.79 | KMT2A (1.00) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL12726822 | 0.79 | KMT2A (0.69) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL1421509 | 0.78 | KMT2A (0.65) | KMT2AMEN1L3MBTL1GAAPOLB | |
| SCHEMBL11120544 | 0.77 | KMT2A (0.63) | KMT2AMEN1L3MBTL1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4450159-A | ORGAN TRANSPLANTS; IMMUNOLOGY | THE UPJOHN COMPANY (US) | 1984-05-22 | — | — | US | claimed |
| US-20110098323-A1 | INHIBITORS OF BACTERIAL BIOFILM FORMATION | MICROBIOTIX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098323-A1 | INHIBITORS OF BACTERIAL BIOFILM FORMATION | MICROBIOTIX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098323-A1 | INHIBITORS OF BACTERIAL BIOFILM FORMATION | MICROBIOTIX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2296476-A1 | INHIBITORS OF BACTERIAL BIOFILM FORMATION | Microbiotix, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009142720-A1 | INHIBITORS OF BACTERIAL BIOFILM FORMATION | MICROBIOTIX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009142720-A1 | INHIBITORS OF BACTERIAL BIOFILM FORMATION | MICROBIOTIX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098323-A1 | INHIBITORS OF BACTERIAL BIOFILM FORMATION | BLVRB, TFPI, FOSB | KMT2A 3896/4885MEN1 4836/4885L3MBTL1 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.